drugset / Trial / NCT04882878

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

NCT04882878

Phase 2 Completed 228 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

Timeline

Start
2021-08-20
Primary completion
2024-04-30
Completion
2024-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Nipocalimab Monoclonal antibody Intravenous